Charles W. Abbott

Charles W. Abbott

Auto-generated profile, based on publicly available information

Charles W. Abbott

Personalis, Inc., Menlo Park, CA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2023 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
RPRachel Marty Pyke
Rachel Marty Pyke
DMDatta Mellacheruvu
Datta Mellacheruvu
SDSteven Dea
Steven Dea
CACharles Abbott
Charles Abbott
SZSimo V. Zhang
Simo V. Zhang
SBSean Michael Boyle
Sean Michael Boyle
Major histocompatibility complex (MHC)–bound peptides that originate from tumor-specific genetic alterations, known as neoantigens, are an important class of anticancer therapeutic targets. Accurately predicting peptide presentation by MHC complexes is a key aspect of discovering therapeutically relevant neoantigens. Technological improvements in mass spectrometry–based immunopeptidomics and advanced modeling techniques have vastly improved MHC presentation prediction over the past 2 decades. However, improvement in the accuracy of prediction algorithms is needed for clinical applications like the development of personalized cancer vaccines, the discovery of biomarkers for response to immunotherapies, and the quantification of autoimmune risk in gene therapies. Toward this end, we generated allele-specific immunopeptidomics data using 25 monoallelic cell lines and created Systematic Human Leukocyte Antigen (HLA) Epitope Ranking Pan Algorithm (SHERPA), a pan-allelic MHC-peptide algorithm for predicting MHC-peptide binding and presentation. In contrast to previously published large-scale monoallelic data, we used an HLA-null K562 parental cell line and a stable transfection of HLA allele to better emulate native presentation. Our dataset includes five previously unprofiled alleles that expand MHC diversity in the training data and extend allelic coverage in underprofiled populations. To improve generalizability, SHERPA systematically integrates 128 monoallelic and 384 multiallelic samples with publicly available immunoproteomics data and binding assay data. Using this dataset, we developed two features that empirically estimate the propensities of genes and specific regions within gene bodies to engender immunopeptides to represent antigen processing. Using a composite model constructed with gradient boosting decision trees, multiallelic deconvolution, and 2.15 million peptides encompassing 167 alleles, we achieved a 1.44-fold improvement of positive predictive value compared with existing tools when evaluated on independent monoallelic datasets and a 1.17-fold improvement when evaluating on tumor samples. With a high degree of accuracy, SHERPA has the potential to enable precision neoantigen discovery for future clinical applications.

19 February 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
BSBahar Saberzadeh-Ardestani
Bahar Saberzadeh-Ardestani
ZLZhenglong Liu
Zhenglong Liu
MSMariam I. Stein
Mariam I. Stein
WSWill A. Sherman
Will A. Sherman
CTChristy E. Trussoni
Christy E. Trussoni
FSFrank Sinicrope
Frank Sinicrope
Purpose: Digital proteomic profiling was performed to identify spatial context in relationship to patient response and survival after anti–PD-1 therapy in metastatic colorectal cancer. Experimental Design: Primary colorectal cancers with deficient mismatch repair from patients treated with anti–PD-1 antibodies were analyzed (N = 30) using digital spatial profiling (GeoMx nCounter). At the invasive margin, 71 proteins were profiled in 10 regions of interest/slide that were segmented into 3 compartments labeled with pan-cytokeratin (epithelia), CD45 (stromal cells), and SYTO13 (nuclei). In an independent cohort (n = 13), digital spatial profiling data and single-cell transcriptomic data were analyzed. Differential protein abundance, after Benjamini–Hochberg correction, was examined by clinical response and progression-free survival (PFS) using multivariable Cox regression. Results: Protein abundance varied significantly between epithelial and stromal compartments. Nonresponders to anti–PD-1 showed higher fibronectin and smooth muscle actin abundance in the epithelial compartment that was associated with significantly shorter PFS (adjusted HR: 6.49 and 4.52, respectively; P < 0.05). In CD45+ stroma, increased expression of proteins related to T cells (CD3 and CD4), NK cells (CD56), antigen presentation (CD40), immune activation (CD27, ICOS), and apoptosis (GZMA) were found in responders (vs nonresponders) to anti–PD-1; each marker was significantly associated with longer patient PFS (0.02 < adjusted HR < 0.17; P < 0.05). In a separate cohort, consistent results by compartment were found for fibronectin and CD56. Gene expression data revealed that fibronectin and smooth muscle actin were primarily derived from cancer-associated fibroblasts. Conclusions: Spatially resolved protein profiles within microenvironments of deficient mismatch repair colorectal cancers can influence patient response and survival after anti–PD-1, highlighting their potential clinical significance.

16 December 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
EGElena Garralda
Elena Garralda
CACharles Abbott
Charles Abbott
ACAlma Calahorro
Alma Calahorro
OMOriol Mirallas
Oriol Mirallas
JPJason Pugh
Jason Pugh
RTRodrigo Toledo
Rodrigo Toledo
Purpose: Prior studies have suggested the biomarker potential of plasma-derived ctDNA in patients with cancer treated with immune checkpoint inhibitors. This study investigated the ability of ctDNA to predict progression-free and overall survival in a cohort of patients with advanced cancer treated with immunotherapies. Experimental Design: In order to characterize the potential role of ultrasensitive ctDNA detection in the management of these patients, we have performed tumor whole-genome sequencing–informed, ultrasensitive ctDNA analysis—tracking approximately 1,800 tumor-specific mutations per patient—in a retrospective cohort (n = 136) and a prospective validation cohort (n = 66) across 24 cancer types treated with immune checkpoint inhibitors alone or in combination with bispecific antibodies or immune cell engagers. Results: Analyzing 1,455 longitudinal samples, we found that ctDNA molecular response measured as early as 3 weeks after treatment initiation correlated with improved progression-free and overall survival, whereas ctDNA clearance at any time strongly correlated with radiologic response and prolonged survival. Additionally, ctDNA dynamics distinguished true progression from pseudoprogression and predicted outcomes in patients receiving continued immunotherapy beyond initial progression. Conclusions: This study highlights the broader applicability of ultrasensitive ctDNA as a biomarker across cancer types and immunotherapy modalities.

21 September 2020 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
MSM. Reza Sailani
M. Reza Sailani
fereshteh jahanbanifereshteh jahanbani
fereshteh jahanbani
CACharles W. Abbott
Charles W. Abbott
HLHayan Lee
Hayan Lee
AZAmin Zia
Amin Zia
MSMichael P Snyder
Michael P Snyder
Essential tremor (ET) is the most common adult-onset movement disorder. In the present study, we performed whole exome sequencing of a large ET-affected family (10 affected and 6 un-affected family members) and identified a TUB p.V431I variant (rs75594955) segregating in a manner consistent with autosomal-dominant inheritance. Subsequent targeted re-sequencing of TUB in 820 unrelated individuals with sporadic ET and 630 controls revealed significant enrichment of rare nonsynonymous TUB variants (e.g. rs75594955: p.V431I, rs1241709665: p.Ile20Phe, rs55648406: p.Arg49Gln) in the ET cohort (SKAT-O test p-value = 6.20e-08). TUB encodes a transcription factor predominantly expressed in neuronal cells and has been previously implicated in obesity. ChIP-seq analyses of the TUB transcription factor across different regions of the mouse brain revealed that TUB regulates the pathways responsible for neurotransmitter production as well thyroid hormone signaling. Together, these results support the association of rare variants in TUB with ET. Essential tremor (ET) is the most common adult-onset movement disorder and in most affected families it appears to be inherited in an autosomal dominant pattern. The causes of essential tremor are unknown. Although many genetic studies in affected families and sporadic cases of ET have shown that genes may play a role, it has proven quite challenging to identify the specific genetic variants involved. Here, we use state-of-the-art technologies to identify the role of genetic variants on ET through exome sequencing of a large affected ET family and subsequent validation in a large population of cases and controls. We show that rare nonsynonymous variants of the TUB gene are significantly enriched in ET cases versus healthy controls. Further studies of biological pathways regulated by TUB in the mouse brain reveal key pathways related to ET. Our work expands our knowledge of the genetic basis of ET.

19 August 2026 in ESMO Open
Verified
Journal Article
Open access
CBC.H. Barcenas
C.H. Barcenas
ACA. Contreras
A. Contreras
AAA. Alexander
A. Alexander
HLH. Lopez
H. Lopez
RYR. Yu
R. Yu
VVV. Valero
V. Valero
Circulating tumor DNA (ctDNA) in early breast cancer (EBC) is prognostic for distant relapses. The ctDNA dynamics in hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative EBC, which is considered low-shedding, are challenging to track. We used an ultrasensitive assay to detect molecular residual disease (MRD) and its association with recurrence in this subtype. Patients with stage II-III HR-positive/HER2-negative EBC were assessed for MRD, in which ctDNA concentrations were measured in serial plasma samples at varying intervals using a whole-genome sequencing tumor-informed assay and the association of ctDNA dynamics with disease recurrence was examined. Twenty-six patients had provided two or more serial plasma samples and had a tumor suitable for DNA sequencing. The median follow-up time was 5.0 years from surgery (range 2.3-10.8 years). Patient-specific ctDNA assays with a median detected ctDNA concentration of 70.2 p.p.m. (interquartile range 14.9-757.0) were designed to test 118 plasma samples (2-9 samples per patient). Eleven patients (42%) had MRD at one or more time points, including preoperative, and 58% of ctDNA detections were in the ultrasensitive range (<100 p.p.m.). Six patients (23%) experienced distant recurrence, consistent with expectation for this subtype within 5 years of follow-up, all of whom had MRD before clinical recurrence (100% sensitivity), with a median lead time of 1.5 years (range 1.0-2.5 years). All 15 patients who remained persistently MRD-negative and 5 patients who experienced ctDNA clearance while receiving oncological treatment remained recurrence-free throughout follow-up. Using an ultrasensitive assay, we found that all patients who experienced distant relapse had MRD detected before clinical detection, with a median lead time of 1.5 years. We observed a strong correlation of ctDNA dynamics with oncological outcomes, with 100% sensitivity of the assay for distant relapse.

19 May 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
FSFrank Sinicrope
Frank Sinicrope
NSNalin Sharma
Nalin Sharma
MMMd Mohiuddin
Md Mohiuddin
BSBahar Saberzadeh-Ardestani
Bahar Saberzadeh-Ardestani
RGRondell P. Graham
Rondell P. Graham
SBSean M. Boyle
Sean M. Boyle
Purpose: Immune checkpoint blockade (ICB) induces frequent and durable responses in metastatic deficient DNA mismatch repair (dMMR) colorectal cancer, yet substantial molecular heterogeneity and resistance remain. We sought to identify candidate tumor- and immune-related biomarkers associated with clinical outcomes following anti–PD-1 therapy. Experimental Design: Consecutive patients with metastatic dMMR colorectal cancer (N = 39) treated with anti–PD-1 therapy underwent tumor profiling using a validated immune-enhanced exome and transcriptome platform. Microsatellite instability (MSI) burden was quantified as the percentage of unstable microsatellite loci using MSIsensor-pro. Associations with objective response were evaluated, and progression-free survival (PFS) and overall survival (OS) were analyzed using Cox proportional hazards models. Results: Higher MSI burden was associated with improved objective response (P = 0.018) and survival. The dichotomized MSI level (Q2–4 vs. Q1) was associated with longer PFS [hazard ratio (HR), 0.18; 95% confidence interval (CI), 0.06–0.56; P = 0.003] and OS (HR, 0.20; 95% CI, 0.07–0.58; P = 0.003), with similar results when modeled continuously. MSI burden correlated with neoantigen clonality but not burden (R = 0.53, P = 0.01). Responders exhibited significantly greater T-cell receptor repertoire diversity; both T- and B-cell receptor diversities were associated with survival. Although human leukocyte antigen (HLA) A, HLA-B, and HLA-C expression was not prognostic, the HLA-B*07:02 allele was associated with the best overall response. In contrast, overexpression of immune exhaustion–related genes and cytotoxic T-cell and natural killer cell exhaustion phenotypes were associated with ICB resistance and poorer prognosis. Conclusions: Integrated exome/transcriptome profiling with MSI quantification identified MSI burden and adaptive immune repertoire diversity as potential correlates of response and survival following ICB. These findings suggest a mechanistic link among genomic instability, antigen recognition diversity, and immunotherapy benefit.